KLRS Stock Summary and Trading Ideas (Kalaris Therapeutics | NASDAQ:KLRS)

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Kalaris Therapeutics trades on the NASDAQ stock market under the symbol KLRS.

As of July 24, 2026, KLRS stock price declined to $3.73 with 156,721 million shares trading.

KLRS has a beta of 2.20, meaning it tends to be more sensitive to market movements. KLRS has a correlation of 0.06 to the broad based SPY ETF.

KLRS has a market cap of $88.75 million. This is considered a Micro Cap stock.

The top ETF exchange traded funds that KLRS belongs to (by Net Assets): VTI, VXF, IWC, DCOR, DFAC.

KLRS has outperformed the market in the last year with a return of +31.3%, while the SPY ETF gained +17.7%. However, in the most recent history, KLRS shares have underperformed the stock market with its stock returning -39.0% in the last 3 month period and -16.0% for the last 2 week period, while SPY has returned +3.8% and -2.1%, respectively.

KLRS support price is $3.61 and resistance is $4.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KLRS shares will trade within this expected range on the day.